Next-Generation Regimens. The Future of Hepatitis C Virus Therapy

John Vizuete, Hope Hubbard, Eric Lawitz

Research output: Contribution to journalArticle

2 Scopus citations

Abstract

The treatment of chronic hepatitis C virus (HCV) has undergone a period of rapid evolution. The era of combination direct antivirals has led to high rates of sustained viral response (SVR), limited toxicities, and more broad applicability across patient demographics. Even current therapies have their limitations, however, including genotype specificity and variable durations of treatment depending on the presence or absence of cirrhosis. Developing a fixed-duration pangenotypic regimen that can broadly treat all stages of fibrosis with equal rates of SVR in all patients, irrespective of treatment experience, is the goal of future therapies. This article reviews antivirals in development.

Original languageEnglish (US)
Pages (from-to)707-716
Number of pages10
JournalClinics in Liver Disease
Volume19
Issue number4
DOIs
StatePublished - Nov 1 2015

Keywords

  • Direct-acting antivirals
  • Genotype 1
  • Hepatitis C
  • Resistance-associated variants
  • Second generation

ASJC Scopus subject areas

  • Hepatology

Fingerprint Dive into the research topics of 'Next-Generation Regimens. The Future of Hepatitis C Virus Therapy'. Together they form a unique fingerprint.

  • Cite this